COVID-19 Can Exacerbate Pattern Hair Loss and Trigger Telogen Effluvium: The Role of Proteoglycan Replacement Therapy with Nourkrin in Clinical Treatment of COVID-19 Associated Hair Loss
December 2020
Studysummary This review discusses the link between COVID-19 and diffuse hair loss, focusing on the potential of proteoglycan replacement therapy with Nourkrin® to treat pattern hair loss and telogen effluvium in affected patients, and reports no new clinical results. Our plain-language summary of this paper — not a Tressless recommendation.
The document "COVID-19 Can Exacerbate Pattern Hair Loss and Trigger Telogen Effluvium – The Role of Proteoglycan Replacement Therapy with Nourkrin® in Clinical Treatment of COVID-19 Associated Hair Loss" from December 2020, discussed how COVID-19 can worsen pattern hair loss and trigger a condition called Telogen Effluvium, a form of temporary hair loss. The paper suggested that Proteoglycan Replacement Therapy with a product called Nourkrin® could be used in the clinical treatment of hair loss associated with COVID-19. However, the document did not provide specific numbers of people involved in the study, making it difficult to assess the strength of the findings.
